Burkly Linda 4
4 · Editas Medicine, Inc. · Filed Mar 5, 2024
Insider Transaction Report
Form 4
Burkly Linda
EVP, CHIEF SCIENTIFIC OFFICER
Transactions
- Award
Common Stock
2024-03-02+24,800→ 69,967 total - Award
Common Stock
2024-03-02+15,055→ 85,022 total - Award
Stock Option (right to buy)
2024-03-02+74,400→ 74,400 totalExercise: $10.53Exp: 2034-03-01→ Common Stock (74,400 underlying)
Footnotes (3)
- [F1]The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028.
- [F2]Reflects the acquisition, upon the achievement of a specified business development milestone, of a portion of a performance-based restricted stock unit award originally granted on July 24, 2023. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on July 24, 2024, subject to continued service.
- [F3]This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028.